Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
34 studies found for:    Von Hippel-Lindau Disease (VHL)

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Completed Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Conditions: Von Hippel-Lindau Disease;   Hemangioblastoma;   Renal Cell Carcinoma;   Pheochromocytoma;   Pancreatic Neuroendocrine Tumor
Intervention: Other: 89Zr bevacizumab PET scan
2 Terminated
Has Results 		Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
Conditions: Von Hippel-Lindau Syndrome;   Renal Cell Carcinoma;   Hemangioblastoma
Intervention: Drug: SU011248
3 Completed
Has Results 		17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Conditions: Hippel-Lindau Disease;   Kidney Cancer
Interventions: Drug: 17 allylamino-17-demethoxygeldanamycin;   Drug: 18 FDG (Fludeoxyglucose 18F);   Drug: [15-O] H2O;   Drug: EPL diluent
4 Active, not recruiting Von Hippel-Lindau Disease Genetic Epidemiology Study
Conditions: Von Hippel Lindau Disease;   Kidney Neoplasms
Intervention:
5 Completed Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Conditions: Von Hippel-Lindau Disease;   Central Nervous System Capillary Hemangioblastoma;   Retinal Capillary Hemangioblastoma
Intervention: Drug: PTK787/ZK 222584
6 Enrolling by invitation Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Condition: Von Hippel-Lindau Disease
Intervention: Drug: Vorinostat
7 Terminated
Has Results 		Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
Condition: Von Hippel-Lindau Syndrome
Intervention: Drug: Sunitinib Malate
8 Completed Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease
Condition: Von Hippel-Lindau Disease
Intervention: Drug: Sunitinib
9 Terminated Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
Conditions: Hemangioblastomas;   Von Hippel Lindau Disease
Intervention: Drug: Avastin
10 Completed EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
Condition: Hippel-Lindau Disease
Intervention: Drug: EYE001
11 Recruiting Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Condition: Von Hippel-Lindau Disease
Intervention:
12 Completed Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
Condition: Von Hippel-Lindau Syndrome
Intervention: Drug: Ranibizumab
13 Recruiting Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients
Condition: Von Hippel-Lindau Disease
Intervention:
14 Active, not recruiting Pazopanib in Von Hippel-Lindau (VHL) Syndrome
Condition: Von Hippel-Lindau Syndrome
Intervention: Drug: Pazopanib
15 Active, not recruiting Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
Conditions: Hemangioblastoma;   Hippel Lindau Disease
Intervention:
16 Completed Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
Conditions: Deafness;   Kidney Diseases;   Kidney Neoplasms;   Neoplasms;   Retinal Diseases
Intervention:
17 Enrolling by invitation Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?
Condition: Von Hippel-Lindaus Disease
Intervention:
18 Terminated TKI 258 in Von Hippel-Lindau Syndrome (VHL)
Condition: Von Hippel-Lindau Syndrome
Intervention: Drug: Dovitinib
19 Completed Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome
Conditions: Kidney Cancer;   Von Hippel-lindau Syndrome
Intervention: Genetic: mutation analysis
20 Not yet recruiting A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Condition: Von Hippel-Lindau Syndrome
Interventions: Drug: Ranibizumab;   Drug: E10030
To Top

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
† Indicates status has not been verified in more than two years